Contrive Datum Insights has published "Bio Banking Market Size, Share & Industry Analysis, By Type (Population-Based Biobank, Disease-Oriented Biobank, Other), Application (Research, Therapeutic, Other), Product & service (Equipment & Storage Systems, Consumables & Reagents, Services), Sample type (Blood Products, Human Tissues, Cell Lines, Others), End user (Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Hospitals & Diagnostic Laboratories, Others), and Regional Forecast, 2026-2034". The study sizes the global bio banking market at USD 83.3 billion in 2025 and projects growth from USD 91.38 billion in 2026 to USD 191.64 billion by 2034, a compound annual growth rate of 9.7% across the forecast period.
Biobanking refers to the collection, processing, cataloguing and long-term storage of human biological specimens (blood, tissue, cells, DNA and RNA) together with the clinical and demographic data linked to each sample. It covers the equipment, consumables and services used to keep those specimens viable for years or decades, from ultra-low-temperature freezers and liquid nitrogen storage to sample tracking and shipping. Buyers include hospitals and diagnostic laboratories building clinical sample archives, pharmaceutical and biotechnology companies sourcing specimens for drug discovery and biomarker research, and academic and public health institutions running long-term population or disease cohort studies.
Expansion of precision medicine and biomarker-driven drug development
Expansion of precision medicine and biomarker-driven drug development is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 9.7% a year, the type lines exposed to it move fastest: Disease-Oriented Biobank compounds at 11.4%, taking its share of revenue from 40% to 46% and its value from USD 33.32 billion to USD 88.15 billion.
On the upside, the study's bull case assumes bull case assumes faster adoption of outsourced biobanking services and accelerated public funding for population cohort programs, pulling forward specimen storage and processing demand, which would take 2034 revenue to USD 214.64 billion rather than the USD 191.64 billion base case.
However, bear case assumes tighter research and biopharma R&D budgets delay new cohort program launches and slow the shift from in-house to outsourced biobanking services, which would hold 2034 revenue to USD 172.48 billion. Population-Based Biobank, which carries 52% of 2025 revenue, already grows at only 8.47% against the market's 9.7%, so the largest part of the base is also its slowest.
Key Players Compete on Population-Based Biobank Volume and Disease-Oriented Biobank Growth
Competition in the global bio banking market runs along the type axis rather than the regional one. Population-Based Biobank holds 52% of 2025 revenue at USD 43.32 billion and remains the largest line through 2034 at 47%, making it the position hardest for a challenger to take. Disease-Oriented Biobank, growing at 11.4%, is where share actually changes hands. A supplier established in one is not thereby established in the other, which is what sustains a field of this size in a market of USD 83.3 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Type | Population-Based Biobank | 52% · USD 43.32 billion | — |
| Application | Research | 58% · USD 48.31 billion | Therapeutic 12.38% |
| Product & service | Equipment & Storage Systems | 42% · USD 34.99 billion | Services 11.87% |
| Sample type | Blood Products | 45% · USD 37.49 billion | Cell Lines 13.26% |
| End user | Academic & Research Institutes | 40% · USD 33.32 billion | Pharmaceutical & Biotechnology Companies 12.14% |
- Based on regional analysis, North America led the global bio banking market in 2025 with 38% of global revenue at USD 31.65 billion, reaching USD 67.07 billion by 2034.
- Asia Pacific takes a rising share of global revenue over the forecast period, from 24% in 2025 to 29% in 2034, with revenue growing from USD 19.99 billion to USD 55.58 billion.
- Middle East and Africa remains the smallest region throughout, at 5% of 2025 revenue and 5% by 2034.
- Disease-Oriented Biobank is projected to grow at 11.4% over the forecast period, the fastest of any type line.
- The United States is the largest single country market at USD 26.9 billion in 2025, 32.29% of global revenue.
The report segments the market across five axes; by type, and by application, product & service, sample type and end user; with revenue and a growth rate for every line in every year from 2020 to 2034, alongside bear, base and bull scenarios for the headline total at USD 172.48 billion and USD 214.64 billion by 2034. It covers all five regions with country-level breakdowns, the competitive landscape, and the research methodology behind every estimate. Delivered as a PDF; a free sample is available on request.